Insperity (NSP) Q3 2025 earnings review
Profitability Crisis Deepens as Healthcare Costs Surge; Management Bets on 2026 Recovery Plan
Insperity reported a severe profitability collapse in Q3, missing expectations with a net loss of $20 million as benefits costs surged an unexpected 9.1%. While revenue grew a modest 4%, Adjusted EBITDA plummeted 74% YoY. Guidance for Q4 implies further losses. The narrative has fully shifted to a 2026 recovery, underpinned by a newly announced, multi-year contract with UnitedHealthcare that management believes will significantly reduce costs and risk. This, combined with aggressive repricing and the rollout of the HRScale/Workday partnership, forms the basis for their expectation to recover a 'majority' of 2025's earnings shortfall next year.
🐂 Bull Case
The new multi-year contract with UnitedHealthcare, which lowers the large claims pooling level to $500k, provides a clear catalyst for margin recovery in 2026. This, combined with aggressive pricing actions, shows management is taking tangible steps to fix the business.
The HRScale solution (with Workday) is officially rolling out, targeting a large, underserved mid-market. Strong Q3 booked sales (+45% YoY) suggest underlying demand for Insperity's core offering remains robust, providing a stable base to launch the new product.
🐻 Bear Case
Management has underestimated the severity of healthcare cost inflation for three consecutive quarters, culminating in a 74% YoY drop in Q3 Adjusted EBITDA and a net loss. This raises questions about forecasting accuracy and control over the single largest cost driver.
The entire recovery thesis hinges on implementing significant price increases without driving away clients during a challenging macro environment. Any misstep could jeopardize the projected earnings rebound.
⚖️ Verdict: 🔴
Bearish. The current financial results are dire, with profitability in freefall and a bleak Q4 outlook. While the 2026 recovery plan, centered on the new UHC contract, is credible, it remains a 'show-me' story with significant execution risk. The market is unlikely to give credit for a 2026 rebound until there is clear evidence that pricing actions are sticking without damaging the client base.
Key Themes
Benefits Cost Crisis Drives Earnings Collapse
The primary issue facing the company is an uncontrolled surge in benefits costs, which rose 9.1% YoY in Q3. This pressure, attributed to higher utilization, pharmacy costs, and even AI-driven billing by providers, directly caused Gross Profit per Worksite Employee to plummet 16% YoY from $247 to $208. The issue has worsened each quarter, resulting in a $20M net loss and a 74% YoY decline in Adjusted EBITDA.
New UnitedHealthcare Contract is the Linchpin for 2026 Recovery
In a significant positive development, Insperity signed a contract extension with UHC through 2028. The new terms provide two key benefits for 2026: 1) direct cost savings and favorable terms projected to offset ~2% of gross benefits costs, and 2) a reduction in the large-claim pooling level from $1M to $500k, materially de-risking the company from catastrophic claims. This agreement is the most critical component of management's plan to restore margins.
HRScale (Workday Partnership) Moves to Commercialization
The strategic partnership with Workday is transitioning from a development project to a commercial product. The official rollout is underway, with co-selling activities initiated and beta clients being onboarded for a March 2026 go-live. Management positions this as a 'category of one' solution for the underserved 150-5,000 employee market, serving as the primary long-term growth catalyst. The OpEx investment for this initiative is expected to decrease by ~$15M in 2026, providing a direct earnings tailwind.
Execution Risk in Aggressive Repricing Strategy
To combat cost inflation, management is implementing significant price increases for new and renewing clients. They state that Q3 retention remained strong at 99% per month. However, the bulk of renewals occurs at year-end. There is a considerable risk that these higher prices, in a 'challenging' macro environment, could lead to elevated client churn, undermining the sales pipeline and offsetting the benefits of repricing.
Strong Underlying Sales Momentum
Despite the severe profitability issues, demand for the core PEO offering appears healthy. Booked sales for the flagship HR360 solution were up 45% YoY in Q3 and 'substantially over budget'. This strong pipeline heading into year-end provides a cushion against potential churn from repricing and is a positive indicator for growth heading into 2026.
Weak SMB Hiring Environment Caps Organic Growth
Management noted that net hiring within the existing client base was negative in Q3, reflecting a challenging macroeconomic environment for small and medium-sized businesses. With this key organic growth lever shut off, the company is entirely reliant on new sales to drive worksite employee growth, increasing the pressure to execute its sales and pricing strategy flawlessly.
Other KPIs
Declined 15% YoY despite a 4% increase in revenue. This negative operating leverage is the clearest indicator of the severe margin pressure from benefits costs, which rose 7% while revenue rose 4%. The entire business model hinges on growing gross profit, and its sharp decline is the central problem.
Decreased 4% YoY, demonstrating disciplined cost control in areas like G&A and salaries. Management is successfully containing costs to partially offset the gross profit collapse and fund the Workday investment. Full-year OpEx is expected to be down ~3% vs. 2024.
Adjusted cash has remained stable, down slightly from $134M at the start of the year. The company continues to fund dividends ($68M YTD) and minimal buybacks ($19M YTD). With a guided net loss in Q4, cash generation will be a key metric to monitor.
Guidance
Reversing. This guidance implies a significant reversal to a loss at the midpoint (-$8M) compared to a $23M profit in Q4 2024. This confirms that the severe margin pressures from Q3 are expected to persist through year-end.
Decelerating. The midpoint of $1.16 represents a steep 68% decline from $3.58 in FY24, reflecting the full-year impact of the benefits cost crisis.
Accelerating/Reversing. Management stated they expect to recover a 'majority' of the earnings shortfall in 2026. The FY25 guidance midpoint for Adjusted EBITDA is ~$136M vs. $270M in FY24, a shortfall of $134M. A majority recovery implies 2026 Adjusted EBITDA could rebound to over $200M, a significant reversal from the current trend.
Key Questions
Quantifying the UHC Contract Impact
Can you elaborate on the 'significant cost reductions' from the new UHC contract? Is the projected 2% favorable impact on 2026 gross benefits costs entirely from this new contract, or does that figure also include expected savings from plan design changes?
Disconnect Between Booked Sales and WSEE Growth
You reported a strong 45% YoY increase in booked sales for Q3, yet the midpoint of your Q4 guidance implies only a 1.6% YoY increase in paid worksite employees. Can you bridge this gap? Is there a longer lag time for new clients to start, or are you seeing higher churn in the existing base that is offsetting these strong new sales?
Renewal Season and Attrition Risk
Regarding the repricing initiative, what percentage of your client base will have gone through a renewal under the new, higher pricing by the end of Q1 2026, and what level of client attrition is baked into your assumption of an earnings recovery?
Countermeasures for AI-Driven Claims Inflation
You've attributed part of the cost surge to AI tools used by healthcare providers for billing. What specific countermeasures are you and UHC developing to combat this new form of 'upcoding' and claims inflation?